Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
127005 trials found · Page 133 of 6351
-
Immunotherapy combo shows promise in stomach cancer trial
Disease control CompletedA randomized, Double-blind, Multicenter, phase III Clinical Study of Comparing the Efficacy and Safety of AK104 Plus Oxaliplatin and Capecitabine (XELOX) Versus Placebo Plus XELOX as First-line Treatment for locally advanced Unresectable or Metastatic Gastric Adenocarcinoma or Ga…
Phase 3 • Sponsor: Akeso • Aim: Disease control
Last updated Jun 27, 2026 07:58 UTC
-
New blood test could spot lung cancer before it spreads
Diagnosis OngoingThis study is part of the development and validation of a non-invasive lung screening test which aim to identify early stage lung cancer in patients at high risk for lung cancer.
Sponsor: Nucleix Ltd. • Aim: Diagnosis
Last updated Jun 27, 2026 07:56 UTC
-
New drug cocktail shows promise against aggressive childhood cancer
Disease control OngoingThis phase III trial compares the safety and effect of adding vinorelbine to vincristine, dactinomycin, and cyclophosphamide (VAC) for the treatment of patients with high risk rhabdomyosarcoma (RMS). High risk refers to cancer that is likely to recur (come back) after treatment o…
Phase 3 • Sponsor: Children's Oncology Group • Aim: Disease control
Last updated Aug 01, 2026 00:00 UTC
-
Weight loss pill shows promise: daily semaglutide helps shed pounds
Disease control CompletedThis study is being conducted to see if semaglutide tablets can be used as a treatment to help people living with overweight or obesity lose weight. This study will look at the change in participants body weight. Participants will either get semaglutide tablets (new medicine) or…
Phase 3 • Sponsor: Novo Nordisk A/S • Aim: Disease control
Last updated Jun 27, 2026 12:31 UTC
-
Can a single eye injection save sight in premature infants?
Disease control CompletedAggressive posterior retinopathy of prematurity (AP-ROP) is a severe form of retinopathy of prematurity that can progress rapidly and lead to retinal detachment and permanent vision loss if not treated promptly. Although laser photocoagulation has traditionally been the standard …
Sponsor: Ain Shams University • Aim: Disease control
Last updated Jul 25, 2026 00:00 UTC
-
Experimental gene therapy hopes to slow rare brain disease in toddlers
Disease control Recruiting nowThe main objective of this trial is to evaluate the safety, tolerability, and pharmacodynamic activity of BBP-812, an investigational AAV9-based gene therapy, in pediatric participants with Canavan disease.
Phase 1/2 • Sponsor: Aspa Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 12:09 UTC
-
New drug combo aims to fight resistant lung cancer
Disease control OngoingA Phase III Clinical Study on Savolitinib Combined with Osimertinib in Treatment of EGFRm+/MET+ Locally Advanced or Metastatic Non-small Cell Lung Cancer
Phase 3 • Sponsor: Hutchison Medipharma Limited • Aim: Disease control
Last updated Jun 27, 2026 13:07 UTC
-
New hope: antiviral cocktail may block hepatitis b in newborns
Prevention OngoingHepatitis B virus is an infection that can be easily transmitted from women to newborns at the time of delivery. Our objective is to identify novel options that are effective and safe in preventing perinatal transmission of hepatitis B in Africa. The REVERT-B study (Reducing Vert…
Phase 3 • Sponsor: University of Alabama at Birmingham • Aim: Prevention
Last updated Aug 26, 2026 00:00 UTC
-
Experimental gene therapy aims to revive lung cancer treatment
Disease control Recruiting nowThe purpose of this randomized study is to determine the safety and efficacy of quaratusugene ozeplasmid (Reqorsa) added to osimertinib in NSCLC patients with activating EGFR mutations who have progressed while on treatment with osimertinib. Quaratusugene ozeplasmid consists of n…
Phase 1/2 • Sponsor: Genprex, Inc. • Aim: Disease control
Last updated Jun 27, 2026 08:12 UTC
-
Can a 'Smart Bridge' in the spine help paralyzed patients walk again?
Disease control CompletedThis research study is being done to test a new device developed for spinal cord injury (SCI) patients. The purpose of this study is to collect data on how the nervous system signals travel within the spinal cord of SCI patients. Once the investigators understand that, they hope …
Sponsor: Rhode Island Hospital • Aim: Disease control
Last updated Aug 16, 2026 00:00 UTC
-
New enzyme therapy gives hope to babies with rare muscle disease
Disease control OngoingThis is a single group, treatment, Phase 3, open-label study to assess efficacy, safety, pharmacokinetic (PK), pharmacodynamics (PD) of avalglucosidase alfa in treatment-naïve male and female participants with IOPD. Study details include: * Study duration: Screening - up to 4 w…
Phase 3 • Sponsor: Sanofi • Aim: Disease control
Last updated Jun 27, 2026 12:05 UTC
-
Blood test could spot hidden cancers early in thousands
Diagnosis OngoingThe Galleri test is a new test that looks for potential signs of cancer in a blood sample. The test can find many different types of cancer but cannot find all cancers. The trial aims to see if using the Galleri test alongside standard cancer testing in the NHS can help to find c…
Sponsor: GRAIL, Inc. • Aim: Diagnosis
Last updated Jul 12, 2026 00:00 UTC
-
Could a monthly shot stop Alzheimer's before it starts? major trial underway.
Prevention OngoingThe main purpose of this study is to evaluate the safety and efficacy of donanemab in participants with preclinical Alzheimer's Disease (AD) over up to 332 weeks. Approximately 800 additional participants will be enrolled in the 12-month Addendum 7 to assess safety of a different…
Phase 3 • Sponsor: Eli Lilly and Company • Aim: Prevention
Last updated Jun 27, 2026 08:12 UTC
-
New drug cocktail aims to fight advanced cervical cancer
Disease control OngoingThis is A Randomized, Double-blind, Placebo-controlled Phase III Study to Evaluate AK104 Plus Platinum-containing Chemotherapy With or Without Bevacizumab as First-line Treatment for Persistent, Recurrent, or Metastatic Cervical Cancer
Phase 3 • Sponsor: Akeso • Aim: Disease control
Last updated Jun 27, 2026 07:58 UTC
-
New pill aims to keep early breast cancer from returning
Disease control OngoingThis is a Phase III, global, randomized, open-label, multicenter, study evaluating the efficacy and safety of adjuvant giredestrant compared with physician's choice of endocrine therapy in participants with medium- and high-risk Stage I-III histologically confirmed estrogen recep…
Phase 3 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Could a lifestyle makeover keep your brain sharp?
Prevention CompletedA study in Finland found that a multidomain intervention of physical activity, nutritional guidance, cognitive training, social activities and management of vascular risk factors slowed cognitive decline in healthy older adults at increased risk of cognitive decline. A 6-month pi…
Sponsor: National University of Singapore • Aim: Prevention
Last updated Aug 12, 2026 00:00 UTC
-
CAR-T therapy takes on multiple myeloma in major new trial
Disease control OngoingThe purpose of this study is to compare the efficacy of Bortezomib, Lenalidomide and Dexamethasone (VRd) induction followed by a single administration of ciltacabtagene autoleucel (cilta-cel) versus VRd induction followed by Lenalidomide and Dexamethasone (Rd) maintenance in newl…
Phase 3 • Sponsor: Janssen Research & Development, LLC • Aim: Disease control
Last updated Aug 30, 2026 00:00 UTC
-
Can reprogrammed immune cells take on a rare thyroid cancer?
Cure OngoingThis is an open-label phase 1 study to assess the safety and feasibility of autologous T cells expressing a single-chain scFv targeting GFRα4 with tandem TCR/CD3ζ and 4-1BB (TCRζ/4-1BB) co-stimulatory domains (referred to as "CART-GFRa4 cells") in patients with incurable medullar…
Phase 1 • Sponsor: University of Pennsylvania • Aim: Cure
Last updated Jul 24, 2026 00:00 UTC
-
New CAR T-Cell therapy aims to tackle tough lymphoma
Disease control Recruiting nowIn the current protocol version, there are two parts. Part I is a pivotal Phase II randomised, multi-centre, open-label study to evaluate the efficacy and safety of MB-CART2019.1 compared to standard of care therapy in participants with relapsed/refractory diffuse large B-cell ly…
Phase 2 • Sponsor: Miltenyi Biomedicine GmbH • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
New Self-Amplifying RNA vaccine shows promise in massive COVID-19 trial
Vaccine CompletedThis is a Phase 1/2/3, randomized, placebo-controlled, observer-blind study designed to evaluate the safety, immunogenicity and efficacy of ARCT-154 in adult participants to be enrolled in Vietnam. This study consists of four parts: Part 1 (Phase 1) will evaluate the safety of …
Phase 2/3 • Sponsor: Vinbiocare Biotechnology Joint Stock Company • Aim: Vaccine
Last updated Jun 27, 2026 07:56 UTC